Benzinga · Mar 4, 2026
BD
NASDAQ · BDMD
Baird Medical Investment Holdings Limited
Healthcare · Medical - Devices
$0.12
Down-$0.01 (-6.75%)
Updated Nov 4, 2026, 9:07 PM
SID Score
2.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 51.82M
- P/E ratio
- 2.44
- Dividend yield
- 0.00%
- 52-week range
- $0.07 – $3.25
- Volume
- 24.91M
- Avg. volume
- 295.81K
Price performance · BDMD
BDMD price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
BDMD closed at $0.12 after 21 trading sessions, down 85.00% for the selected period.
- Last close
- $0.12
- Period change
- -85.00%
- Period low
- $0.12
- Period high
- $0.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.1051 | $0.137 | $0.0931 | $0.117 | 24.91M |
| Nov 2, 2026 | $0.1959 | $0.196 | $0.0725 | $0.138 | 169.24M |
| Oct 30, 2026 | $0.18 | $0.27 | $0.1333 | $0.1604 | 9.66M |
| Oct 29, 2026 | $0.25 | $0.2534 | $0.1619 | $0.188 | 905.57K |
| Oct 28, 2026 | $0.2461 | $0.29 | $0.23 | $0.25 | 393.46K |
| Oct 27, 2026 | $0.342 | $0.4558 | $0.2253 | $0.2819 | 1.53M |
| Oct 26, 2026 | $0.4455 | $0.4739 | $0.4111 | $0.4277 | 58.35K |
| Oct 23, 2026 | $0.45 | $0.475 | $0.445 | $0.4455 | 59.57K |
| Oct 22, 2026 | $0.4706 | $0.491 | $0.4526 | $0.453 | 35.55K |
| Oct 21, 2026 | $0.462 | $0.5489 | $0.462 | $0.476 | 31.47K |
| Oct 20, 2026 | $0.436 | $0.4858 | $0.436 | $0.4816 | 58.05K |
| Oct 19, 2026 | $0.569 | $0.6004 | $0.40 | $0.436 | 186.5K |
| Oct 16, 2026 | $0.60 | $0.6412 | $0.55 | $0.566 | 53.92K |
| Oct 15, 2026 | $0.552 | $0.6185 | $0.55 | $0.60 | 79.98K |
| Oct 14, 2026 | $0.6853 | $0.7136 | $0.5108 | $0.5505 | 127.26K |
| Oct 13, 2026 | $0.6779 | $0.7308 | $0.6779 | $0.6849 | 43.83K |
| Oct 12, 2026 | $0.74 | $0.80 | $0.66 | $0.7495 | 67.17K |
| Oct 9, 2026 | $0.7663 | $0.8076 | $0.76 | $0.77 | 50.15K |
| Oct 8, 2026 | $0.77 | $0.83 | $0.77 | $0.79 | 66.98K |
| Oct 7, 2026 | $0.74 | $0.8121 | $0.74 | $0.79 | 64.46K |
| Oct 6, 2026 | $0.73 | $0.8022 | $0.73 | $0.7801 | 42.41K |
Latest BDMD news
The latest Smart Investors Daily articles mentioning BDMD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BDMD research
Overview
Company profile and research snapshot.
Company profile
Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Mar 4, 2026
Reported Earlier: Baird Medical Investment Completes Cross-Platform AI Surgical Software, Begins U.S., EU, And China Registration
Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of development for its
Benzinga · Feb 25, 2026
Baird Medical shares are trading higher after the company announced new clinical progress across the US in interventional thyroidology.
Benzinga · Feb 25, 2026
Baird Medical Investment Holdings Expands U.S. Clinical Adoption Of Minimally Invasive Thyroid Treatments
Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced new clinical progress across the United
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
